



Summary of Studies Supporting USDA Product Licensure

Establishment Name	Intervet Inc.
USDA Vet Biologics Establishment Number	165A
Product Code	1501.20
True Name	Equine Influenza Vaccine, Modified Live Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Flu Avert I.N. - Merck Animal Health Flu Avert I.N. - No distributor specified
Date of Compilation Summary	February 08, 2018

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy									
Pertaining to	Equine Influenza Virus (EIV)									
Study Purpose	To demonstrate efficacy against EIV									
Product Administration	One dose administered intranasally (IN).									
Study Animals	13 vaccinates and 9 controls horses were used at 8.5 months of age.									
Challenge Description	All horses were challenged with EIV strain A/equine/Kentucky/99 36 days post vaccination.									
Interval observed after challenge	Horses were observed daily for 14 days post-challenge for clinical signs. Nasal swabs were collected daily for virus isolation.									
Results	<p>A horse was considered affected if virus isolation was detected at any occasion postchallenge.</p> <table border="1"> <thead> <tr> <th>Group</th> <th># of Animals</th> <th>Virus Isolation</th> </tr> </thead> <tbody> <tr> <td>Vaccinates</td> <td>13</td> <td>8 (61%)</td> </tr> <tr> <td>Controls</td> <td>9</td> <td>9 (100%)</td> </tr> </tbody> </table> <p>Raw data shown on attached pages.</p>	Group	# of Animals	Virus Isolation	Vaccinates	13	8 (61%)	Controls	9	9 (100%)
Group	# of Animals	Virus Isolation								
Vaccinates	13	8 (61%)								
Controls	9	9 (100%)								
USDA Approval Date	September 7, 2005									

Study Type	Efficacy
Pertaining to	Equine Influenza Virus (EIV)
Study Purpose	To demonstrate efficacy against EIV six months after vaccination
Product Administration	One dose administered intranasally (IN).
Study Animals	19 vaccinates and 10 controls horses were used at 11-12 months of age.
Challenge Description	All horses were challenged with EIV strain A/equine/Kentucky/91 six months post vaccination.
Interval observed after challenge	Horses were observed daily for 10 days post-challenge for clinical signs. Nasal swabs were collected daily for virus isolation.
Results	Raw data shown on attached pages.
USDA Approval Date	May 20, 1999

Table A. Rectal temperature observations post-challenge.

Group	Study Day	Day post-challenge													
		Pre-challenge					Post-challenge								
	Haller No.	-3	-2	-1	0	1	2	3	4	5	6	7	8	9	10
Vaccinates (Group C)	31	100.9*	100.5	101.1	100.4	100.4	104.7	102.5	100.2	102.6	100.0	100.0	100.2	100.0	100.0
	32	100.5	100.4	100.2	101.0	101.5	104.1	103.6	104.1	104.1	103.0	100.2	99.8	99.5	100.3
	33	100.4	100.5	101.2	101.4	100.2	104.1	104.0	102.7	101.2	100.9	100.2	101.2	100.1	100.8
	35	99.6	100.5	100.6	100.1	101.4	103.2	99.9	99.8	101.1	102.5	100.0	99.8	99.4	100.1
	37	101.2	100.2	101.0	101.2	100.9	103.6	100.3	100.4	100.7	100.2	100.6	100.6	100.3	100.4
	39	100.5	100.3	100.1	100.8	100.3	103.0	100.7	100.3	100.3	100.9	100.6	101.2	100.4	100.2
	41	100.5	100.2	100.3	101.1	101.1	103.9	100.3	100.1	100.3	100.3	100.3	100.1	100.4	100.2
	42	100.4	100.6	100.4	100.2	100.5	101.7	100.2	100.5	101.2	101.2	103.4	102.5	100.9	100.3
	45	100.1	100.9	100.2	100.3	100.4	104.3	104.8	106.2	105.7	103.4	103.2	100.5	100.5	100.1
	46	100.7	101.3	100.5	99.6	100.7	102.7	102.3	102.3	100.4	102.9	101.7	101.7	101.8	100.8
47	100.6	101.1	101.4	101.6	101.3	105.4	105.3	102.6	104.9	103.3	102.3	102.3	100.9	100.9	
48	100.6	100.8	100.2	100.8	100.2	101.8	100.1	100.1	100.5	100.1	100.5	99.6	99.7	99.8	
50	100.6	101.2	100.3	100.4	100.3	104.2	101.2	100.8	100.1	100.2	101.0	101.0	100.2	100.4	
52	100.1	100.5	100.9	100.6	99.6	102.0	100.9	100.2	99.5	99.7	99.8	100.2	100.2	99.7	
53	101.1	100.2	100.8	100.5	100.5	104.0	100.2	99.9	101.4	101.0	101.0	101.0	101.0	100.5	
54	100.3	100.7	101.2	100.0	100.5	102.8	103.5	102.2	101.5	103.4	100.7	100.7	100.9	100.0	
57	100.6	101.4	100.5	100.7	100.2	104.3	100.1	101.0	100.4	101.2	99.9	100.2	100.2	99.9	
58	100.3	100.9	101.8	101.0	99.9	100.2	100.4	100.2	100.7	100.0	100.0	100.2	100.2	100.1	
59	99.9	100.4	100.6	100.8	100.4	105.0	104.6	104.0	104.7	105.1	101.3	100.5	101.4	100.2	
34	101.0	100.7	100.9	101.2	100.5	103.4	101.2	101.3	104.7	105.1	100.5	101.4	100.2	100.6	
36	100.4	100.7	100.8	101.0	100.2	105.6	103.2	100.1	100.8	100.2	100.5	100.8	100.2	100.2	
38	100.7	100.9	100.1	100.7	100.3	105.3	104.1	104.1	101.8	102.1	101.1	101.7	103.1	102.5	
40	100.7	100.7	100.6	100.9	100.2	104.2	104.5	105.5	105.6	104.6	104.6	101.2	100.1	100.0	
43	100.3	100.2	100.5	100.5	100.5	104.6	103.6	104.7	103.9	104.2	100.2	100.0	100.2	101.6	
44	100.5	101.2	100.4	101.0	100.2	104.8	103.6	101.5	102.5	102.9	101.9	104.0	99.1	99.6	
49	100.9	100.9	101.6	101.1	100.7	106.0	105.8	105.1	104.5	105.3	102.0	100.0	99.6	99.6	
51	101.1	100.5	100.7	100.3	100.6	105.5	104.8	101.6	104.6	102.2	103.1	100.2	100.2	100.3	
55	100.9	100.4	100.5	100.2	100.6	105.0	104.5	105.0	104.7	103.7	104.4	103.2	99.8	100.1	
56	100.7	101.1	100.9	100.6	100.4	104.1	102.3	102.9	105.0	105.2	104.8	101.9	100.3	100.3	

*All temperatures in degrees Fahrenheit.

Table B. Clinical observations by clinical sign post-challenge.

Study day		178				179				180				181				182				183				184							
Day post-challenge		-3				-2				-1				0				1				2				3							
Group	Halter No.	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D
Vaccinates (Group C)	31	0	0	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	0	0	0	0	1	0	0
	32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	2	2	0	0
	33	0	0	0	0	0	2	0	0	0	2	0	0	0	1	0	0	0	1	0	0	0	2	0	0	0	2	0	0	0	2	0	0
	35	0	2	0	0	0	2	0	0	0	1	0	0	0	2	0	0	2	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0
	37	0	0	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	0	0	0	2	3	0	0	0	0	0	0	3	0	0	0
	39	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0	2	3	0	0
	41	0	1	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	2	0	0	1	2	0	1	0	3	0	0	0	0	0	0
	42	0	0	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	1	3	0	0	0	0	0	2	2	0	0
	45	0	0	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	2	2	0	0
	46	0	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0
	47	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	1	0	0	0	2	2	0	0	2	2	0
	48	0	2	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0
	50	0	1	0	0	0	2	0	0	0	2	0	0	0	1	0	0	0	0	0	0	1	1	0	0	1	3	0	0	0	0	0	0
	52	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	1	2	0	0	0	0	0	3	0	0	0
	53	0	0	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0	1	0	0	1	2	0	0	0	0	0	0	3	0	0	0
54	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	2	2	0	0	2	2	0	0	2	3	0	0	
57	0	2	0	0	0	2	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0	3	0	0	0	2	2	0	0	2	2	0	
58	1	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	1	2	0	1	0	2	0	0	0	0	0	0	
59	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	2	2	0	1	0	0	0	0	
Controls (Group D)	34	0	0	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	1	0	0	0	3	0	0	0	2	3	0	0	0	0	0
	36	0	0	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	3	0	0	0	0	3	0	0	0	0	0
	38	0	2	0	0	0	2	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	2	0	0	2	3	0	0	0	0	0	0
	40	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	2	1	0	0	0	0	0
	43	0	0	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	0	0	0	2	2	0	0	0	0	3	0	0	0	0	0
	44	0	1	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	1	0	0	0	0	1	0	0	0	0	0
	49	0	2	0	0	0	2	0	0	0	2	0	0	0	0	0	0	0	2	0	0	1	3	0	0	2	3	0	1	0	0	0	0
	51	0	0	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0	0	0	0	0	2	0	0	2	3	1	0	0	0	0	0
55	0	2	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0	0	0	0	0	1	0	1	2	3	0	0	0	0	0	0	
56	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	2	0	0	2	2	0	0	0	0	0	0	

- * C, coughing
- N, nasal discharge
- R, respiration
- D, depression

Table 2. Clinical signs and scoring index.

Clinical Sign	Description	Score
Coughing	normal during observation period of 15 min	0
	coughing once during observation	1
	coughing twice or more during observation	2
Nasal discharge	normal	0
	abnormal, serous	1
	abnormal, mucopurulent	2
	abnormal, profuse	3
Respiration	normal	0
	abnormal (dyspnea, tachypnea)	1
Depression	normal	0
	depression present [†]	1

[†]Depression was assessed by subjective evaluation of individual animal behavior that included the following: failure to approach food rapidly, general lethargy, inappetence, and anorexia.

Table B (continued). Clinical observations by clinical sign post-challenge.

Study day		185				186				187				188				189				190				191											
Day post-challenge		4				5				6				7				8				9				10											
Group	Halter No.	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D	C	N	R	D				
Vaccinates (Group C)	31	0*	3	0	0	1	1	0	0	1	0	0	0	1	2	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0
	32	2	3	0	0	2	2	0	0	0	3	1	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	1	0	0				
	33	1	3	0	0	0	3	0	0	2	3	0	0	0	3	0	0	0	3	0	0	2	3	0	0	0	2	0	0	0	2	0	0				
	35	1	3	0	0	1	3	0	0	1	3	0	0	0	3	0	0	2	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	37	0	3	0	0	0	2	0	0	1	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0				
	39	1	3	0	0	0	3	0	0	0	3	0	0	1	3	0	0	2	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	41	0	3	0	0	0	2	0	0	0	2	0	0	0	3	0	0	0	3	0	0	1	2	0	0	0	2	0	0	0	2	0	0				
	42	0	2	0	0	1	3	0	0	2	3	0	0	1	3	0	0	2	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	45	2	2	1	0	2	3	1	0	0	3	1	0	0	3	0	0	1	3	1	0	0	3	0	0	0	2	0	0	0	2	0	0				
	46	0	3	0	0	1	3	0	0	2	3	0	0	0	2	3	0	0	2	3	0	0	2	3	0	0	2	3	0	0	2	3	0				
	47	0	3	0	0	2	2	1	0	2	3	1	0	2	3	0	0	0	3	0	0	0	2	3	0	0	2	3	0	0	2	3	0				
	48	1	2	0	0	1	2	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0	1	2	0	0	0	0	0	0	0	0	0				
	50	0	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0	0	2	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	52	0	3	0	0	0	0	0	0	0	3	0	0	0	3	0	0	0	2	0	0	1	3	0	0	0	3	0	0	0	2	0	0				
	53	0	0	0	0	0	0	0	0	0	2	0	0	0	3	0	0	1	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	54	2	3	0	0	2	3	0	0	2	3	0	0	1	3	0	0	1	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	57	1	2	0	0	0	2	0	0	0	2	0	0	0	3	0	0	0	3	0	0	0	1	3	0	0	0	3	0	0	0	3	0				
58	0	2	0	0	0	2	0	0	0	2	0	0	0	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0					
59	2	3	1	1	2	3	1	1	2	2	1	1	2	3	0	0	2	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0					
Controls (Group D)	34	1	3	0	0	0	3	0	0	1	3	0	0	2	3	0	0	2	3	0	0	1	3	0	0	1	3	0	0	1	3	0	0				
	36	2	3	0	0	2	3	0	0	2	3	0	0	2	3	0	0	2	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	38	2	3	0	0	2	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0	2	3	0	0	1	3	0	0	1	3	0	0				
	40	0	3	0	0	0	3	0	0	2	2	0	0	0	3	1	1	2	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	43	2	3	1	1	2	3	0	0	1	3	1	1	1	3	1	1	0	3	0	0	0	3	0	0	0	1	3	0	0	1	3	0				
	44	2	3	0	0	0	3	1	0	1	3	0	0	2	3	0	0	2	3	0	0	1	3	0	0	1	3	0	0	1	3	0	0				
	49	2	3	0	1	2	3	0	1	1	3	0	1	0	3	0	0	1	3	0	0	1	3	0	0	1	3	0	0	0	3	0	0				
	51	0	3	0	0	1	3	0	0	1	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0	0	3	0	0				
	55	0	2	0	0	2	3	1	1	2	3	1	1	0	3	1	1	2	3	1	0	1	3	1	0	1	3	1	0	0	3	0	0				
56	1	2	0	0	2	3	0	0	2	3	0	1	2	3	1	1	2	3	1	0	2	3	0	0	0	3	0	0	0	3	0	0					

- * C, coughing
- N, nasal discharge
- R, respiration
- D, depression

Table 2. Clinical signs and scoring index.

Clinical Sign	Description	Score
Coughing	normal during observation period of 15 min	0
	coughing once during observation	1
	coughing twice or more during observation	2
Nasal discharge	normal	0
	abnormal, serous	1
	abnormal, mucopurulent	2
	abnormal, profuse	3
Respiration	normal	0
	abnormal (dyspnea, tachypnea)	1
Depression	normal	0
	depression present [†]	1

[†]Depression was assessed by subjective evaluation of individual animal behavior that included the following: failure to approach food rapidly, general lethargy, inappetence, and anorexia.

Table C. Virus shedding post-challenge detected by cell culture.

Study day	179	182	183	184	185	186	187	188	189		
Days post-challenge	-1	1	2	3	4	5	6	7	8		
Group	Halter No.	Detection of virus*									No. days positive per horse
Vaccinates	31	neg**	1.0E+02	1.0E+02	neg	1.8E+02	neg	neg	neg	neg	3
	32	neg	neg	5.6E+02	1.8E+02	3.9E+03	1.8E+02	neg	neg	neg	4
	33	neg	2.5E+05	3.2E+05	3.9E+04	2.3E+03	neg	neg	5.6E+02	neg	5
	35	neg	1.0E+05	2.5E+04	1.8E+03	1.0E+05	neg	neg	neg	neg	4
	37	neg	1.8E+02	3.2E+04	3.9E+02	3.2E+03	neg	neg	neg	neg	4
	39	neg	1.0E+03	3.2E+05	2.9E+03	3.2E+04	3.2E+03	neg	neg	neg	5
	41	neg	5.6E+02	3.2E+04	5.6E+03	1.8E+03	neg	neg	neg	neg	4
	42	neg	4.0E+03	4.4E+04	neg	2.5E+04	neg	neg	neg	neg	3
	45	neg	neg	3.2E+04	6.3E+03	3.2E+03	1.0E+04	1.0E+03	neg	neg	5
	46	neg	neg	1.0E+05	3.2E+05	1.8E+05	4.0E+02	neg	neg	neg	4
	47	neg	3.2E+03	3.2E+05	2.5E+03	2.5E+05	5.0E+02	neg	neg	neg	5
	48	neg	neg	3.2E+03	2.0E+03	1.0E+04	neg	neg	neg	neg	3
	50	neg	3.2E+03	3.9E+04	6.3E+03	5.0E+03	5.6E+03	neg	neg	neg	5
	52	neg	neg	1.0E+05	1.0E+02	3.2E+03	2.5E+02	neg	neg	neg	4
	53	neg	neg	5.6E+04	1.0E+04	3.2E+03	neg	neg	neg	neg	3
	54	neg	5.0E+03	4.0E+04	3.9E+03	5.6E+04	7.4E+03	2.5E+02	neg	neg	6
	57	neg	neg	1.8E+04	2.0E+02	1.0E+03	neg	neg	neg	neg	3
	58	neg	2.5E+02	1.8E+02	neg	3.2E+02	neg	neg	neg	neg	3
	59	neg	2.5E+02	2.5E+05	3.9E+03	3.2E+03	3.2E+02	neg	neg	neg	5
No. horses positive per day (of 19)		0	12	19	16	19	9	2	1	0	
Controls	34	neg	3.2E+05	3.2E+05	5.6E+03	3.2E+05	5.6E+03	5.6E+03	neg	neg	6
	36	neg	5.6E+03	1.8E+05	1.4E+02	3.9E+04	3.2E+03	neg	neg	neg	5
	38	neg	1.0E+05	5.6E+04	1.8E+05	1.0E+04	neg	NT [‡]	neg	neg	4
	40	neg	1.8E+02	3.2E+05	3.9E+04	2.5E+04	2.5E+03	neg	1.8E+02	neg	6
	43	neg	4.0E+03	3.2E+04	3.9E+03	1.0E+04	1.8E+03	1.0E+03	neg	neg	6
	44	neg	neg	1.0E+05	3.2E+05	3.9E+03	NT	2.5E+03	neg	neg	4
	49	neg	1.0E+03	3.2E+05	2.5E+03	3.9E+03	3.2E+03	1.8E+02	neg	neg	6
	51	neg	2.0E+03	2.5E+05	2.3E+03	3.9E+03	5.6E+03	1.0E+03	neg	neg	6
	55	neg	1.8E+02	5.6E+04	2.5E+03	1.0E+04	1.4E+03	2.3E+02	2.5E+02	neg	7
	56	neg	3.2E+02	3.2E+05	3.9E+04	5.6E+03	2.5E+03	2.3E+02	neg	neg	5
No. horses positive per day (of 10 or 9)		0	9	10	10	10	8	7	2	0	

*Values are in TCID₅₀ units per ml of sample (1.0E+02 corresponds to 1.0 x 10²).

**Negative: less than 1.0E+01 (assay detection limit).

‡Not tested.

Study Type	Safety																										
Pertaining to	ALL																										
Study Purpose	To demonstrate safety under field conditions																										
Product Administration	One dose administered intranasally. Four horses in Study 2 were given a 2 nd dose intranasally 3 months after initial vaccination.																										
Study Animals	Study 1: 435 horses from 6 states. 53 horses were 11 months of age or younger at time of vaccination. 11 pregnant mares were enrolled. Study 2: 47 horses from 3 states. 46 horses were 6 months of age or younger at time of vaccination.																										
Challenge Description	Not applicable																										
Interval observed after challenge	Horses were observed immediately following vaccination and then daily for 14 days post-vaccination.																										
Results	<p>Study 1:</p> <table border="1"> <thead> <tr> <th>Adverse Events</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Nasal Discharge</td> <td>22</td> </tr> <tr> <td>Ocular Discharge</td> <td>3</td> </tr> <tr> <td>Coughing</td> <td>2</td> </tr> <tr> <td>Urticaria</td> <td>3</td> </tr> <tr> <td>Founder</td> <td>1</td> </tr> <tr> <td>Swelling</td> <td>1</td> </tr> <tr> <td>Fever (>102.0°F)</td> <td>1</td> </tr> <tr> <td>Lethal white foal</td> <td>1</td> </tr> <tr> <td>Horses with no reaction</td> <td>407</td> </tr> </tbody> </table> <p>Study 2:</p> <table border="1"> <thead> <tr> <th>Adverse Events</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Nasal Discharge</td> <td>2</td> </tr> <tr> <td>Horses with no reaction</td> <td>45</td> </tr> </tbody> </table>	Adverse Events	Number	Nasal Discharge	22	Ocular Discharge	3	Coughing	2	Urticaria	3	Founder	1	Swelling	1	Fever (>102.0°F)	1	Lethal white foal	1	Horses with no reaction	407	Adverse Events	Number	Nasal Discharge	2	Horses with no reaction	45
Adverse Events	Number																										
Nasal Discharge	22																										
Ocular Discharge	3																										
Coughing	2																										
Urticaria	3																										
Founder	1																										
Swelling	1																										
Fever (>102.0°F)	1																										
Lethal white foal	1																										
Horses with no reaction	407																										
Adverse Events	Number																										
Nasal Discharge	2																										
Horses with no reaction	45																										
USDA Approval Date	September 23, 1999																										